Search Results

You are looking at 31 - 40 of 126 items for :

  • "papillary" x
  • Refine by Access: All x
Clear All
Full access

Eric Jonasch

,” noted Dr. Jonasch. Amplification of the MET gene has been identified in both papillary and clear cell RCCs, revealed Dr. Jonasch. In fact, high total MET expression has been linked to shorter PFS and overall survival in patients with metastatic RCC

Full access

Philip J. Saylor and M. Dror Michaelson

transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis . Clin Cancer Res 1995 ; 1 : 913 – 920 . 50 Prewett M Rothman M Waksal H . Mouse-human chimeric

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael Baine, Kathryn Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi Haas, Steven L. Hancock, Payal Kapur, Christos Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon Manley, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey Sosman, Mary A. Dwyer, Lisa A. Gurski, and Angela Motter

, with a median age at diagnosis of 64 years. 2 Approximately 85% of kidney tumors are RCC, and approximately 70% of these have a clear cell histology (ccRCC). 3 – 5 Other less common cell types include papillary, chromophobe, translocation, and Bellini

Full access

Rishi Agarwal, Jiang Wang, Keith Wilson, William Barrett, and John C. Morris

(undifferentiated) carcinoma of thyroid, with lymphovascular and perineural invasion that also involved the adjoining esophagus and jugular vein; 1 of 3 lymph nodes was positive for metastatic carcinoma. Two separate papillary thyroid microcarcinomas, 0.4 and 0.1 cm

Full access

Tanner M. Johanns, George Ansstas, and Sonika Dahiya

, 5 These observations, along with encouraging early-phase data in other histologies, such as papillary thyroid cancer 6 and hairy cell leukemia, 7 which both have high frequencies of BRAF V600E mutations, have led to increasing interest in

Full access

Presenter: Philippe E. Spiess

persistent disease, particularly in patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk NMIBC specifically with carcinoma in situ with or without papillary bladder tumors. Other topical issues in the field include recently standardized

Full access

R. Michael Tuttle, Robert I. Haddad, Douglas W. Ball, David Byrd, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, William M. Lydiatt, Judith McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann, and Miranda Hughes

(1) differentiated (including papillary, follicular, and Hürthle cell); (2) medullary (MTC); and (3) anaplastic (aggressive undifferentiated tumor). Of 55,554 patients diagnosed with thyroid carcinoma between 2007 and 2011, 88.0% had papillary

Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, Amanda Nickles Fader, Christine M. Fisher, David K. Gaffney, Suzanne George, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole McMillian, and Miranda Hughes

DM 2nd Gehrig PA Fader AN Olawaiye AB . Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review . Gynecol Oncol 2009 ; 115 : 142 – 153 . 181. Olawaiye AB Boruta DM 2nd . Management of

Full access

study to evaluate the efficacy of combination sorafenib and temsirolimus in patients with thyroid cancer of follicular cell origin (e.g., papillary, follicular, Hürthle cell, anaplastic). Primary Outcome Measures: Determine the objective response

Full access

Center, New York, NY This is a phase II study to evaluate the efficacy of the combination sorafenib with temsirolimus in patients with thyroid cancer of follicular cell origin (e.g., papillary, follicular, Hurthle cell). Primary Outcome Measures